GLUE
Monte Rosa Therapeutics, Inc.
$19.39
-2.12%
2026-05-08
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Key Fundamentals
P/E Ratio
56.38
Forward P/E
-11.39
EPS (TTM)
$-1.56
ROE
-32.6%
Revenue Growth (YoY)
-95.0%
Profit Margin
0.0%
Debt/Equity
7.49
Price/Book
5.53
Beta
1.62
Market Cap
$1.66B
Avg Volume (10D)
691K
Recent Breakout Signals
No recent breakout signals detected for GLUE.
Recent Price Range (60 Days)
60D High
$21.62
60D Low
$14.20
Avg Volume
944K
Latest Close
$19.39
Get breakout alerts for GLUE
Sign up for Breakout Scanner to receive daily notifications when GLUE triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Monte Rosa Therapeutics, Inc. (GLUE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GLUE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GLUE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.